- 現金殖利率: 5.78%、總殖利率: 5.78%、5年平均現金配發率: 77.68%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 6.26 | 7.56 | 4.50 | 7.14 | 0.00 | 0 | 71.88 | -0.39 | 0.00 | 0 | 71.88 | -0.39 |
| 2024 (4) | 5.82 | 28.48 | 4.20 | 20.0 | 0.00 | 0 | 72.16 | -6.6 | 0.00 | 0 | 72.16 | -6.6 |
| 2023 (3) | 4.53 | 2.95 | 3.50 | 2.94 | 0.00 | 0 | 77.26 | -0.01 | 0.00 | 0 | 77.26 | -0.01 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | 1.78 | 45.9 | 13.38 | 1.44 | 67.44 | 24.14 | 1.78 | -71.61 | 13.38 |
| 25Q4 (7) | 1.22 | -47.64 | -43.26 | 0.86 | -36.76 | -1.15 | 6.27 | 24.16 | 7.55 |
| 25Q3 (6) | 2.33 | 104.39 | 55.33 | 1.36 | 13.33 | 4.62 | 5.05 | 85.66 | 37.23 |
| 25Q2 (5) | 1.14 | -27.39 | 8.57 | 1.20 | 3.45 | 53.85 | 2.72 | 73.25 | 24.77 |
| 25Q1 (4) | 1.57 | -26.98 | 0.0 | 1.16 | 33.33 | 0.0 | 1.57 | -73.07 | 0.0 |
| 24Q4 (3) | 2.15 | 43.33 | 0.0 | 0.87 | -33.08 | 0.0 | 5.83 | 58.42 | 0.0 |
| 24Q3 (2) | 1.50 | 42.86 | 0.0 | 1.30 | 66.67 | 0.0 | 3.68 | 68.81 | 0.0 |
| 24Q2 (1) | 1.05 | 0.0 | 0.0 | 0.78 | 0.0 | 0.0 | 2.18 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/6 | 6.17 | 19.05 | 15.28 | 31.74 | 6.84 | 16.54 | N/A | 1.06 | 4.54 | - |
| 2026/5 | 5.18 | 0.03 | -3.59 | 25.57 | 4.98 | 16.36 | N/A | 0.58 | 3.48 | - |
| 2026/4 | 5.18 | -13.59 | 17.92 | 20.39 | 7.39 | 14.78 | N/A | 0.6 | 2.9 | - |
| 2026/3 | 6.0 | 66.75 | 5.77 | 15.2 | 4.21 | 15.2 | 0.92 | 1.18 | 2.31 | - |
| 2026/2 | 3.6 | -35.9 | -12.06 | 9.21 | 3.22 | 15.62 | 0.9 | 0.24 | 1.12 | - |
| 2026/1 | 5.61 | -12.53 | 16.17 | 5.61 | 16.17 | 16.9 | 0.83 | - | ||
| 2025/12 | 6.42 | 31.66 | 3.14 | 64.53 | 9.48 | 16.62 | 0.84 | 0.75 | 8.53 | - |
| 2025/11 | 4.87 | -8.62 | 7.04 | 58.11 | 10.23 | 19.0 | 0.73 | 0.51 | 7.78 | - |
| 2025/10 | 5.33 | -39.36 | -16.01 | 53.24 | 10.53 | 18.71 | 0.74 | 0.51 | 7.27 | 去年公費流感疫苗營收主要認列在10月，今年則在9月 |
| 2025/9 | 8.79 | 92.08 | 45.12 | 47.91 | 14.57 | 18.2 | 0.78 | 1.94 | 6.75 | 主係公費及自費疫苗營收於本月認列 |
| 2025/8 | 4.58 | -5.12 | 3.21 | 39.11 | 9.4 | 14.76 | 0.96 | 0.54 | 4.81 | - |
| 2025/7 | 4.83 | -9.84 | -0.16 | 34.53 | 10.27 | 15.56 | 0.91 | 0.62 | 4.27 | - |
| 2025/6 | 5.35 | -0.44 | 12.99 | 29.71 | 12.19 | 15.12 | 0.84 | 0.71 | 3.66 | - |
| 2025/5 | 5.38 | 22.37 | 21.04 | 24.36 | 12.02 | 15.44 | 0.82 | 0.48 | 2.95 | - |
| 2025/4 | 4.39 | -22.49 | -3.78 | 18.98 | 9.7 | 14.15 | 0.89 | 0.4 | 2.48 | - |
| 2025/3 | 5.67 | 38.63 | 42.55 | 14.59 | 14.55 | 14.59 | 0.83 | 0.93 | 2.07 | - |
| 2025/2 | 4.09 | -15.32 | 48.96 | 8.92 | 1.83 | 15.06 | 0.8 | 0.38 | 1.14 | - |
| 2025/1 | 4.83 | -21.31 | -19.68 | 4.83 | -19.68 | 15.52 | 0.78 | 0.76 | 0.76 | - |
| 2024/12 | 6.14 | 34.85 | 20.81 | 58.86 | 6.9 | 17.04 | 0.75 | 0.79 | 6.59 | - |
| 2024/11 | 4.55 | -28.3 | -6.45 | 52.72 | 5.5 | 16.96 | 0.75 | 0.25 | 5.8 | - |
| 2024/10 | 6.35 | 4.77 | -2.24 | 48.17 | 6.79 | 16.85 | 0.75 | 0.65 | 5.55 | - |
| 2024/9 | 6.06 | 36.6 | 3.36 | 41.81 | 8.3 | 15.33 | 0.94 | 0.96 | 4.89 | - |
| 2024/8 | 4.44 | -8.22 | 4.72 | 35.75 | 9.18 | 14.01 | 1.03 | 0.41 | 3.94 | - |
| 2024/7 | 4.83 | 2.04 | 14.28 | 31.32 | 9.84 | 14.01 | 1.03 | 0.64 | 3.53 | - |
| 2024/6 | 4.74 | 6.64 | 8.93 | 26.48 | 9.07 | 13.75 | 0.81 | 0.6 | 2.88 | - |
| 2024/5 | 4.44 | -2.73 | -9.25 | 21.75 | 9.1 | 12.99 | 0.86 | 0.53 | 2.28 | - |
| 2024/4 | 4.57 | 14.82 | 35.46 | 17.3 | 15.08 | 11.29 | 0.99 | 0.27 | 1.75 | - |
| 2024/3 | 3.98 | 44.87 | -6.71 | 12.74 | 9.19 | 12.74 | N/A | 0.3 | 1.48 | - |
| 2024/2 | 2.75 | -54.34 | -19.22 | 8.76 | 18.36 | 13.59 | N/A | 0.2 | 1.18 | - |
| 2024/1 | 6.01 | 24.53 | 50.29 | 6.01 | 50.29 | 15.71 | N/A | 0.97 | 0.97 | 因適逢農曆春節連續假期客戶備貨與子公司認列藥證移轉收入所致。 |
| 2023/12 | 4.83 | -0.86 | 12.11 | 54.8 | 8.27 | 16.2 | N/A | -0.06 | 5.6 | - |
| 2023/11 | 4.87 | -25.0 | -19.38 | 49.97 | 7.91 | 17.23 | N/A | 0.36 | 5.66 | - |
| 2023/10 | 6.5 | 10.78 | 30.47 | 45.1 | 12.01 | 16.59 | N/A | 0.51 | 5.31 | - |
| 2023/9 | 5.86 | 38.4 | 10.29 | 38.61 | 9.4 | 14.33 | N/A | 1.08 | 5.02 | - |
| 2023/8 | 4.24 | 0.15 | 3.32 | 32.74 | 9.24 | 12.85 | N/A | 0.68 | 3.93 | - |
| 2023/7 | 4.23 | -3.44 | 9.96 | 28.51 | 10.18 | 13.51 | N/A | 0.49 | 3.25 | - |
| 2023/6 | 4.38 | -10.51 | 16.81 | 24.31 | 10.37 | 12.65 | N/A | 0.47 | 2.77 | - |
| 2023/5 | 4.9 | 45.2 | 17.05 | 19.93 | 9.04 | 12.53 | N/A | 0.7 | 2.29 | - |
| 2023/4 | 3.37 | -20.92 | -9.44 | 15.03 | 6.67 | 11.03 | N/A | 0.41 | 1.59 | - |
| 2023/3 | 4.26 | 25.44 | 16.09 | 11.66 | 12.45 | 11.66 | N/A | 0.51 | 1.18 | - |
| 2023/2 | 3.4 | -15.05 | 29.54 | 7.4 | 10.46 | 11.71 | N/A | 0.25 | 0.67 | - |
| 2023/1 | 4.0 | -7.1 | -1.81 | 4.0 | -1.81 | 14.35 | N/A | 0.42 | 0.42 | - |
| 2022/12 | 4.31 | -28.71 | -8.86 | 50.62 | 11.59 | 15.33 | N/A | 0.29 | 5.66 | - |
| 2022/11 | 6.04 | 21.37 | 40.21 | 46.31 | 13.97 | 16.34 | N/A | 0.63 | 5.37 | 本月營收包含部份公費流感疫苖銷售及認列「Amphotericin B」微脂體產品權利金收入 |
| 2022/10 | 4.98 | -6.34 | -11.86 | 40.27 | 10.86 | 14.39 | N/A | 0.42 | 4.74 | 本月營收包含部分公費流感疫苖銷售 |
| 2022/9 | 5.32 | 29.66 | 36.44 | 35.29 | 15.05 | 13.26 | N/A | 0.84 | 4.35 | 本月出貨部分流感疫苖 |
| 2022/8 | 4.1 | 6.58 | 23.59 | 29.97 | 11.93 | 11.69 | N/A | 0.53 | 3.51 | - |
| 2022/7 | 3.85 | 2.75 | 13.57 | 25.87 | 10.28 | 11.77 | N/A | 0.41 | 2.98 | - |
| 2022/6 | 3.74 | -10.49 | 20.48 | 22.02 | 9.7 | 11.65 | N/A | 0.41 | 2.57 | - |
| 2022/5 | 4.18 | 12.32 | 10.41 | 18.28 | 7.72 | 11.58 | N/A | 0.52 | 2.16 | - |
| 2022/4 | 3.72 | 1.37 | 5.25 | 14.09 | 6.95 | 10.02 | N/A | 0.49 | 1.64 | - |
| 2022/3 | 3.67 | 39.98 | 13.95 | 10.37 | 7.57 | 10.37 | N/A | 0.44 | 1.16 | - |
| 2022/2 | 2.62 | -35.62 | 1.34 | 6.7 | 4.37 | 11.43 | N/A | 0.25 | 0.72 | - |
| 2022/1 | 4.08 | -13.86 | 6.42 | 4.08 | 6.42 | 13.12 | N/A | 0.47 | 0.47 | - |
| 2021/12 | 4.73 | 9.78 | 26.82 | 45.36 | 7.44 | 14.69 | N/A | 0.51 | 4.36 | - |
| 2021/11 | 4.31 | -23.7 | 37.61 | 40.63 | 5.56 | 13.85 | N/A | 0.45 | 3.85 | 本月營業收入因銷售國內流感疫苗而增加 |
| 2021/10 | 5.65 | 44.99 | 9.34 | 36.32 | 2.72 | 12.86 | N/A | 0.74 | 3.4 | 本月及去年同期皆因銷售國內流感疫苗而增加 |
| 2021/9 | 3.9 | 17.45 | -4.65 | 30.67 | 1.59 | 10.6 | N/A | 0.59 | 2.67 | - |
| 2021/8 | 3.32 | -2.06 | 9.56 | 26.78 | 2.57 | 0.0 | N/A | 0.32 | 2.07 | - |
| 2021/7 | 3.39 | 9.08 | 8.15 | 23.46 | 1.65 | 0.0 | N/A | 0.36 | 1.76 | - |